Biosimilars for Australian Dermatologists.

IF 2.2 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2025-02-05 DOI:10.1111/ajd.14427

Grace X Li, Mona Marabani, Deshan F Sebaratnam

引用次数: 0

Abstract

Biosimilars offer the potential for substantial cost savings within the Australian healthcare system. This is particularly salient in dermatology, where biologics are used to treat chronic skin diseases and cost savings will be accrued throughout the life of a patient. However, uptake of biosimilars in clinical practice has been hindered by barriers including insufficient clinician education, concerns about safety and efficacy, and negative patient perception. Increased availability of biosimilars promotes long-term sustainability of the Pharmaceutical Benefits Scheme and may help maintain equitable access to healthcare across Australia.

查看原文本刊更多论文

澳大利亚皮肤科医生的生物仿制药。

生物仿制药为澳大利亚医疗保健系统节省大量成本提供了可能。这一点在皮肤科尤为突出，因为皮肤科使用生物制剂治疗慢性皮肤病，在患者的整个生命周期中都可以节约成本。然而，生物仿制药在临床实践中的应用一直受到各种障碍的阻碍，包括临床医生教育不足、对安全性和有效性的担忧以及患者的负面看法。增加生物仿制药的供应量可促进药品福利计划的长期可持续性，并有助于在澳大利亚全国范围内保持医疗保健的公平性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.